At Inferre Consulting, we stand for the principle of bringing in innovative ideas and solutions to help our clients to deduce the best strategies for their success. Read more about us here.
Here we present summary of five recent case studies, derived from our ongoing market research projects highlighting recent development in the Pharma world.
Building Collaborative Networks: Pharma and Healthcare Integration
Collaborate to reduce patient harm, accelerate innovation, and cut operational costs.
Focusing on
- AstraZeneca‘s RSV Prevention: Collaborative Nirsevimab Development (2023-2024)
- Sanofi’s Enhancing Diabetes Care through Strategic Alliances (2024 & Ongoing)
Key Findings
- Lack of collaboration leads to 25,000 annual deaths in USA from treatment errors.
- 30% slower development: Absence of collaboration delays drug innovation and new therapies
- 25% higher costs: Ineffective collaboration increases operational costs, limiting resources for care and research.
Building Collaborative Networks: Pharma and Healthcare Integration
Implementing Personalized Medicine in Pharma
Need of Personalized Medicine for Better Quality of Life.
Focusing on
- Merck Group: Pioneering Personalized Cancer Vaccines (2021-2024)
- Amgen: Advancing Precision Medicine (2021-2024)
key Findings
- 75% of cancer patients do not respond to standard therapies, highlighting the need for targeted treatments.
- US$ 495.3 to US$ 672.7 billion cost annually due to adverse reactions.
- 70% of cancer are diagnosed at advanced stages, where personalized medicine can enable earlier intervention and better outcomes.
Implementing Personalized Medicine in Pharma
Leveraging Technology to Improve Drug Development Processes
Innovate to cost-cut, boost early success, and predict Phase III outcomes.
Focusing on
- GSK‘s AI strategy speeds up Hepatitis B therapy through patient classification (2024)
- Eli Lilly and Company‘s Automated Innovation: Transforming Drug Discovery with Robotics (2023)
Key findings
- $2.5 billion Cost to develop a drug, with fewer than 14% of Phase 1 candidates achieving FDA approval.
- 8x R&D spending has increased over 35 years, yet annual approvals for new molecular entities remain stagnant.
- 40–50% Drugs fail in Phase III due to challenges in predicting efficacy and safety.
Leveraging Technology to Improve Drug Development Processes
Streamlining Regulatory Compliance in Pharma: Best Practices
Navigating Compliance Challenges for Competitive Advantage.
Focusing on
- Roche‘s Compliance Management Strategies (2020-2024)
- Johnson & Johnson: Transforming Compliance and Regulatory Efficiency (2020-2024)
Key findings
- 70% Pharma companies report difficulties in adapting to evolving regulations.
- 50% increase in compliance-related penalties over the past three years.
- 60% of employees lack adequate training on new regulatory requirements.
Streamlining Regulatory Compliance in Pharma: Best Practices
The Value of Data Driven Decision Making in Healthcare
Enhancing Patient Outcomes Through Data-Driven Solutions.
Focusing on
- Recent Success Story of Novartis (2021-24).
Key findings
- 33% Reduction in hospital readmissions achieved through personalized care plans, as reported by the National Institutes of Health.
- 20% Increase in treatment adherence, leading to improved overall patient outcomes.
- US$ 1.5 Million Annual Savings realized from effective data management strategies.
The Value of Data Driven Decision Making in Healthcare
Contact us here for more detail about our services
Author Information
The individual reports are part of Inferre Consulting‘s market research projects which is led by Ritav Brahmbhatt. Content of this publication is prepared by Ritav Brahmbhatt and summarized here by Avisek Ghose.
Disclaimer
The information provided in this newsletter does not constitute financial or investment advice. Always consult with a qualified professional before making any investment decisions.
This presentation is based on publicly available information and does not contain any proprietary data or commercial interests. The insights shared are intended solely for educational purposes. No financial support or sponsorship was received from any pharmaceutical companies or related entities for the development of this content.
The authors took extreme care for citing credits wherever applicable, however, in case of missing citation(s) and/or any other discrepancies, please inform the authors, Avisek Ghose and Ritav Brahmbhatt with valid documentation(s).
Author: Avisek Ghose
Published on 09 Dec. 2024
Inferre Consulting GmbH 